Am J Prev Med by Khoury, Muin J. et al.
Precision Public Health for the Era of Precision Medicine
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The Precision Medicine Initiative1 promises a new healthcare era. A proposed 1 million—
person cohort could create a deeper understanding of disease causation. Improvements in 
quality of sequencing, reduction in price, and advances in “omic” fields and biotechnology 
promise a new era, variably labeled personalized or precision medicine. Although genomics 
is one driver of precision health care, other factors may be as important (e.g., health 
information technology).
Both excitement and skepticism met the announcement. 2 Public health experts are 
concerned about the disproportionate emphasis on genes, drugs, and disease, while 
neglecting strategies to address social determinants of health. A prime concern for public 
health is promoting health, preventing disease, and reducing health disparities by focusing 
on modifiable morbidity and mortality. In 2014, CDC estimated the annual number of 
potentially preventable deaths from the top five causes in the U.S.3 Data suggest that at least 
one third of deaths are potentially preventable by reducing prevalence of known risk factors 
(e.g., smoking, poor diet, and inadequate physical activity).
Could the same technologies that propel precision medicine usher in a parallel era of 
“precision public health” beyond treatment of sick individuals? If precision medicine is 
about providing the right treatment to the right patient at the right time, precision public 
health can be simply viewed as providing the right intervention to the right population at the 
right time. More-accurate methods for measuring disease, pathogens, exposures, behaviors, 
and susceptibility could allow better assessment of population health and development of 
policies and targeted programs for preventing disease. The initial drive toward precision 
public health is occurring, but much more work lies ahead to develop a robust evidentiary 
foundation for use. The following are examples of priority areas.
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 Role of Multidisciplinary Public Health Sciences
Though precision medicine focuses on individualized care, its success truly requires a 
population-based approach. To learn what interventions work for whom, data on each 
individual need to be compared with data from large, diverse numbers of people to identify 
population subgroups likely to respond differently to interventions. In addition, collecting 
information from large numbers of people is far more informative when diverse people are 
included from the underlying population. Using data from convenience samples alone (i.e., 
collected without regard to important factors such as race/ethnicity, age, and sex) can lead to 
selection bias and unreliable prediction models. To guard against selection bias, a strong 
epidemiologic cohort design is needed to ensure diversity and representation of the 
underlying population, as well as unbiased assessment of genetic and environmental 
factors.4
Additionally, successful implementation requires multiple disciplines (e.g., research on 
patient-centered outcomes, comparative effectiveness, communication). A multidisciplinary 
science agenda goes beyond traditional bench to bedside. For precision medicine to succeed, 
a population perspective is needed. Education of patients, families, physicians, payers, and 
the public health community will be needed. This is where strong public health—healthcare 
partnerships are essential in assessing the needs of individuals and communities, developing 
effective policies and guidelines, ensuring that all people have access to the intended 
benefits, and tracking cost-effectiveness outcomes in the real world.
 Shifting the Focus From Treatment to Prevention
A compelling case can be made for more attention to prevention and early detection. 
Although personalized treatments can help save the lives of sick people, prevention applies 
to all. “Precision prevention” may be helpful in using both science and limited resources for 
targeting prevention strategies. For example, recent data suggest that knowing the speed with 
which people metabolize nicotine, based on genetic and other factors, could lead to 
personalized smoking-cessation interventions. Another approach to precision prevention is 
increased screening of people at greater risk for cancer. Family health history is an 
inexpensive tool for identifying individuals and families that require earlier and more 
intensive screening for breast and ovarian cancer.5 Although whole genome sequencing in 
healthy populations will require more evidence for its utility, there is an emerging list of 
genomic applications that merit a targeted public health approach to find people with 
selected genetic conditions (e.g., hereditary breast/ovarian and colorectal cancers and 
familial hypercholesterolemia). Collectively, these conditions affect around 2 million people 
in the U.S., with evidence-based interventions that are poorly implemented in health care.6
In addition, new biomarkers promise to improve the understanding of disease natural history. 
For example, epigenetics7 is providing insights into the impact of the environment on gene 
expression throughout life with the possibility of targeted interventions. There is also strong 
suspicion that cumulative epigenetic changes due to environmental stressors may explain 
population health disparities in the burden of various diseases among disadvantaged 
populations.8 Measuring neighborhood-specific epigenetic alterations can potentially be 
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used to investigate causes for health disparities. However, although the field of epigenetics is 
promising for public health, much more work is needed in developing, validating, and using 
the right platforms in population studies.8
Biomarkers are only one of many avenues for identifying high-risk populations for 
intervention. Public health programs already use targeted approaches, for example, by 
recommending screening for hepatitis C in people born from 1945 through 1965, and 
identifying people with prediabetes. Public health policies that will enhance lower sugar 
intake, weight control, and increased activity levels across the population could be 
accompanied, but not replaced, by more-targeted efforts to find people with prediabetes 
based on age, family history, and BMI. As technologies mature, there will be increasing 
opportunities for additional targeting for a wide variety of disease-prevention efforts.
Precision prevention has evidentiary challenges; prevention guidelines are typically designed 
to apply to average individuals in the population. It is not straightforward, without data on 
the balance of benefits and harms, to develop evidence-based prevention recommendations 
that apply to subsets of the population defined by traditional risk factors as well as new 
“omic” markers. Most chronic diseases are due to multiple factors. With a few exceptions, 
the full complement of heritability explained by common genetic variants is unknown. 
Epidemiologic studies continue to suggest that genetic risk prediction for many chronic 
conditions does not add more information to risk prediction based on simple measures such 
as BMI, lipids and activity levels, or educational attainment. Also, specific genomic 
information may not be clinically actionable even when it is a risk factor. Finally, the 
analysis of genetic—environmental interactions in population studies is still in its infancy. 
Large numbers of people are needed to make sense of subgroup data. Most genetic risk 
factors have weak effects on risks of chronic diseases. These studies contain a relatively 
small number of research subjects; therefore, stratification of disease risk based on risk 
factors leaves most people either “slightly above average or “slightly below average” risk. 
Thus, the evidence accumulated so far makes it difficult to recommend different courses of 
action to preserve health for most people.
 Improving Early Detection of Pathogens and Infectious Disease 
Outbreaks
Another emerging priority is the use of genomics in the early detection and investigation of 
infectious disease outbreaks. The increasing availability and affordability of genomic 
technologies is changing the practice of microbiology. These technologies deliver more-
precise information on infectious agents while reducing reliance on time-consuming and 
costly diagnostic methods. Enhanced bioinformatics capacity is revolutionizing the ability to 
detect and respond to infectious disease threats. In 2014, CDC launched the Advanced 
Molecular Detection Infectious Disease Initiative9 to improve the ability to detect outbreaks 
sooner and respond more effectively, saving lives and reducing cost. Recent studies show the 
growing utility of whole genome sequencing in investigations of hospital infectious disease 
outbreaks,5,10 and foodborne outbreaks.11 Methods of pathogen genomics are also used in 
the study of genetic variants in infectious diseases, the prediction of antibiotic resistance, 
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and assessing vaccine safety and effectiveness. However, growth in their applications and 
more work to assess the reliability of new methods, including specificity, sensitivity, and 
positive and negative predictive values, are anticipated. Beyond genomics, simple 
approaches such as call data records from mobile phones could eliminate the need for 
retrospective reporting by infected individuals of their previous locations and contacts. 
Ultimately, new tools will need to provide added value to explaining the complexity of 
infectious disease at the population level, given the multitude of factors involved (e.g., 
environmental, individual’s vulnerability, migration patterns, immunologic diversity, and 
epigenetic mechanisms).
 Modernizing Public Health Surveillance, Epidemiology, and Information 
Systems
A priority for public health is the use of information technology and data science in 
enhancing public health surveillance and tracking. Surveillance is the systematic, ongoing 
collection, management, analysis, and interpretation of data to stimulate and guide action. 
The best-recognized use of surveillance is the detection of epidemics and community health 
problems. Big data has the potential to accelerate early detection of outbreaks and other 
community health issues.4 New technologies will accelerate timeliness and completeness of 
electronic laboratory reporting for notifiable conditions. Tracking population movements 
and contact of potentially infected individuals can also be modernized using available 
technologies. For example, during the West African Ebola outbreak, mobile phone data 
provided objective, real-time information on location and movement of people to pre-empt 
future outbreaks.7
Population data are also used to detect changes in health behaviors, monitor changes in 
environmental exposures, and evaluate control measures. The quality of surveillance will 
improve owing to new data sources, such as electronic health records, and communication 
methods, such as mobile technologies. More-accurate laboratory technologies will allow 
tracking of trends in environmental exposures and disease outcomes. The growth of 
interconnectivity in digital information can be used to monitor health both at the individual 
and population levels. Population disease surveillance systems, such as cancer registries, 
will benefit from enhanced refined diagnostic classification of diseases by adding molecular 
markers of etiology and treatment response as exemplified by the recent National Cancer 
Institute report to the nation on the status of cancer (e.g., HER2 mutations in breast 
cancer).12
CDC’s new surveillance strategy13 will jump start accelerated use of tools to improve 
availability, quality, and timeliness of data, and linking public health data more effectively 
with clinical systems. A radical transformation is taking place in epidemiology, the 
fundamental science of public health, to include and integrate disparate sources of data. As 
with precision medicine, separating signal from noise will not be easy. A healthy dose of 
skepticism may be needed to guard against the overpromise of big data. For example, in 
2013, when influenza hit the U.S. hard, Google monitored the outbreak using analysis of 
influenza-related Internet searches, drastically overestimating peak influenza levels, 
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compared with public health surveillances.14 Even more problematic could be the potential 
for many false alarms by mindless examination, on a large scale, leading to putative 
associations between big data points and disease outcomes. This process may falsely infer 
causality and could potentially lead to faulty interventions. As the authors discuss in detail 
elsewhere,4 separating signal from noise will require epidemiologic study designs that 
minimize bias, robust knowledge integration process, adherence to principles of evidence-
based medicine and population screening, and a robust multidisciplinary translational 
research agenda that goes beyond initial discoveries to implement findings in populations.4
 Challenges Ahead
Despite opportunities for precision public health, many challenges lie ahead. The added 
value of new tools and approaches to public health practice needs to be evaluated just like 
precision tools should be evaluated in medicine. A sustainable informatics capacity is also 
needed to enhance connectivity and interoperability of clinical, laboratory, and public health 
systems. Various ethical and social issues should be addressed, such as privacy, protection of 
genomic data from being used against employment and health insurance, and informed 
consent on storing and using genetic and nongenetic information for research and 
development. Precision public health will also require human capital, infrastructure, and 
education of the public health workforce, as well empowering the general public with 
accurate information. Finally, the many policy implications of using precision tools in public 
health need to be addressed. For example, epigenetic data, if validated in large-scale data, 
could be used to address health disparities and environmental justice. Moreover, a more 
effective balance needs to be achieved in the research and implementation of both precision 
medicine and precision public health. These are the early days of precision public health and 
it is not just about genes, drugs, and disease.
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